Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ADA 2020: Medtronic Explains Strategy To Return Growth To Diabetes Business

Executive Summary

Medtronic will launch its next-generation MiniMed 780G insulin pump while continuing to develop complementary technologies to close the competitive gap with its rivals in the diabetes market.

You may also be interested in...



ATTD 2022: Mic Drop Moment As Medtronic Presents 780G Data Proving Closed Loop Ability

Results of the ADAPT study presented at the Advanced Technologies & Treatments for Diabetes conference in Barcelona support Medtronic’s hope that the 780g insulin pump will help to turn around its diabetes business or make it an attractive acquisition for another company.

Que Dallara Takes Over Medtronic Diabetes At A Critical Moment

Dallara is joining Medtronic from Honeywell, where she served as CEO of the conglomerate’s Connected Enterprise. The company also promoted Mike Marinaro to the president of Medtronic’s surgical robotics unit and Kweli Thomson to lead the cardiac rhythm management unit.

Medtronic Reviews Its Portfolio, Driving Speculation It May Sell Diabetes Unit

During its recent quarterly earnings call, Medtronic CEO Geoff Martha reiterated that the company expects to announce changes over the next year that will help it drive growth and shareholder value. Analysts suspect Medtronic’s struggling diabetes business is probably the top candidate for a sale.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT142311

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel